Cyclooxygenase-2 (COX-2) detection in tumors is becoming a critical tool for predicting the outcome of various chemotherapy treatments, including advanced lung cancer and breast cancer. COX-2 is ...read more
Cyclooxygenase-2 (COX-2) detection in tumors is becoming a critical tool for predicting the outcome of various chemotherapy treatments, including advanced lung cancer and breast cancer.
COX-2 is an important biomarker because it is significantly overexpressed in inflamed tissues and some cancer cells while normal tissues do not express COX-2. An imaging agent that can non-invasively detect COX-2 in early stage cancer cells can be a valuable tool in personalizing drug treatment for patients.
XenoLight RediJect COX-2 probe is one of the range of XenoLight reagents for PerkinElmer’s IVIS and Nuance optical imaging systems. RediJect COX-2 probe is a novel fluorescent imaging probe that specifically detects the COX-2 biomarker noninvasively in vivo and ex vivo in tissue sections. The COX-2 probe in conjunction with the IVIS imaging system provides the ability to non-invasively detect COX-2 in early-stage cancer cells, with a level of sensitivity and accuracy not attainable by conventional methods.
PerkinElmer’s Nuance Microscopy imaging system with its liquid crystal tunable filter (LCTF) sets can be used to detect COX-2 in vitro in cancer cells and in fixed tissue sections from tumors where COX-2 is up-regulated. Nuance’s spectral unmixing feature efficiently separates COX-2 targeting signal from other fluorescent signal and tissue autofluorescence
Write a review
Sharing your experience will help scientists like you. Achieve Reviewer Status and Win an iPad air (All reviews published will be entered into the next drawing on March 30th 2014).